Apr 12, 2022 8:00 am EDT Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis
Feb 10, 2022 4:05 pm EST Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
Jan 24, 2022 8:00 am EST Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria
Dec 15, 2021 8:00 am EST Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing
Nov 22, 2021 8:00 am EST Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021
Nov 15, 2021 8:00 am EST Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021